2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧13 min
Tarjoustasot
First North Sweden
Määrä
Osto
49 648
Myynti
Määrä
51 196
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 900 | - | - | ||
| 112 | - | - | ||
| 2 | - | - | ||
| 250 | - | - | ||
| 4 876 | - | - |
Ylin
0,309VWAP
Alin
0,29VaihtoMäärä
0,5 1 820 563
VWAP
Ylin
0,309Alin
0,29VaihtoMäärä
0,5 1 820 563
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·21 t sittenWhere do we think the price is moving towards this year 0,4sek
·2 t sittenThey have just scaled up production for the second time. I expect an increase again by summer. The share price has not changed since the first time, which will soon lead to an upward jump when the effect of the sales is in Acarix's pocket. In addition, the company's expenses have constantly become proportionally smaller. Countless calculations can be made, but 1-2,5 kroner is within reach by year-end. This is just playing with numbers, and not a call to buy.
·13.2.Aamir to Redeye today: "Doubling our production capacity in a very near future"
·2 päivää sittenWonderful news. It will be needed. Not a moment too soon.
·1 päivä sittenHere's something about what I was talking about. What I am referring to is the incredibly important milestone where the CADScor system received its own unique CPT code (Category I CPT code) in the US healthcare system. In practice, this is what is called getting "its own line in the system," and it changes everything for the business model. Here are the most important points about what this means for Acarix: Direct payment (Reimbursement): Before the code was introduced, doctors and hospitals had to struggle with manual paperwork or use more generic codes to get the costs of a CADScor test covered. With its own line in the system, there is now an established procedure and a clear price for what insurance companies (including Medicare) must pay for a test. Massive growth in the USA: The code truly came into effect in January 2024. This is the primary reason why we saw the explosive growth in the US market during 2025, which we have just seen in the annual report. This makes it extremely much easier for sales teams (like those from CompleMed) to convince cardiologists to adopt the system, because they now know exactly how they will get their money back. Price per test: The average reimbursement in the USA is now around 300 USD per test. Since a patch only costs a fraction of this, it is a very good business for medical clinics to use CADScor as the primary screening tool. Validation: Obtaining a "Category I CPT code" is a long and difficult process at the AMA (American Medical Association). It serves as a seal of approval for the technology and proves that the method is clinically recognized and necessary. This is absolutely essential regarding Acarix's "moat" (protection against competitors). It's not just any "line in the system" – it's a line built around their completely unique, patented technology. Here's how they have "locked" the market so others can't just copy them: 1. The CPT code is "tailored" for acoustics When Acarix received their CPT code in the USA (originally 0714T, now often billed under more established codes), it was described specifically as an "acoustic analysis of heart sounds via AI." Why this is good for you: If a competitor comes with a new machine that, for example, measures electrical impulses (ECG) or heat, they cannot use Acarix's line in the system. They would have to start all over again applying for their own code – a process that takes many years and costs millions. 2. Patents: The technical wall Acarix holds over 45 patents across 12 patent families. These patents cover not just the machine itself, but the very way they filter out noise and find the very faint "murmurs" (turbulence) in the coronary arteries. No shortcuts: Other companies may not use the same mathematical method to analyze the sound. They must invent a completely new way to do it without infringing on Acarix's rights. 3. The "first-mover" advantage They are the first to have had this written into the system as a recognized method. Doctors' habit: Once cardiologists have learned to use "acoustic rule-out" and have entered the code into their medical record systems, they are very reluctant to switch to something else. The database: Acarix has data from over 60,000 patients. Their AI is "trained" better than anyone else's because they have the largest library of heart sounds in the world. A competitor starts with 0 data. Conclusion: They have created a situation where they are the "gatekeeper" for acoustic cardiac diagnostics. If others want to enter this market, they must either: Spend 5-10 years developing their own (different) technology and clinical studies. Or (which is more likely in MedTech) buy Acarix to gain access to their patents and their "line in the system." This is precisely why a strategy of holding the stock long-term makes sense. The more they get "written into" official medical guidelines, the more valuable their patented "line" becomes.- ·13.2.
- 13.2.13.2.Acarix (Q4 review): A solid end to 2025 Research Update Friday February 13 Redeye provides an update following Acarix’s Q4 2025 report. We view the report and recent activities positively, highlighting the continued growth in patch sales and CADScor system deliveries in the US, alongside progress in other key markets through its partner-led model. Following the report, we have made some revisions to our estimates, primarily regarding our projected US revenue ramp-up and the company’s ongoing geographical expansion.
- ·13.2.I believe it will go up when a good order comes in or if there is a new approval. Otherwise, it will probably go up and down for a while longer. I am, however, staying in the boat now.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧13 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenWhere do we think the price is moving towards this year 0,4sek·2 t sittenThey have just scaled up production for the second time. I expect an increase again by summer. The share price has not changed since the first time, which will soon lead to an upward jump when the effect of the sales is in Acarix's pocket. In addition, the company's expenses have constantly become proportionally smaller. Countless calculations can be made, but 1-2,5 kroner is within reach by year-end. This is just playing with numbers, and not a call to buy.
- ·13.2.Aamir to Redeye today: "Doubling our production capacity in a very near future"·2 päivää sittenWonderful news. It will be needed. Not a moment too soon.·1 päivä sittenHere's something about what I was talking about. What I am referring to is the incredibly important milestone where the CADScor system received its own unique CPT code (Category I CPT code) in the US healthcare system. In practice, this is what is called getting "its own line in the system," and it changes everything for the business model. Here are the most important points about what this means for Acarix: Direct payment (Reimbursement): Before the code was introduced, doctors and hospitals had to struggle with manual paperwork or use more generic codes to get the costs of a CADScor test covered. With its own line in the system, there is now an established procedure and a clear price for what insurance companies (including Medicare) must pay for a test. Massive growth in the USA: The code truly came into effect in January 2024. This is the primary reason why we saw the explosive growth in the US market during 2025, which we have just seen in the annual report. This makes it extremely much easier for sales teams (like those from CompleMed) to convince cardiologists to adopt the system, because they now know exactly how they will get their money back. Price per test: The average reimbursement in the USA is now around 300 USD per test. Since a patch only costs a fraction of this, it is a very good business for medical clinics to use CADScor as the primary screening tool. Validation: Obtaining a "Category I CPT code" is a long and difficult process at the AMA (American Medical Association). It serves as a seal of approval for the technology and proves that the method is clinically recognized and necessary. This is absolutely essential regarding Acarix's "moat" (protection against competitors). It's not just any "line in the system" – it's a line built around their completely unique, patented technology. Here's how they have "locked" the market so others can't just copy them: 1. The CPT code is "tailored" for acoustics When Acarix received their CPT code in the USA (originally 0714T, now often billed under more established codes), it was described specifically as an "acoustic analysis of heart sounds via AI." Why this is good for you: If a competitor comes with a new machine that, for example, measures electrical impulses (ECG) or heat, they cannot use Acarix's line in the system. They would have to start all over again applying for their own code – a process that takes many years and costs millions. 2. Patents: The technical wall Acarix holds over 45 patents across 12 patent families. These patents cover not just the machine itself, but the very way they filter out noise and find the very faint "murmurs" (turbulence) in the coronary arteries. No shortcuts: Other companies may not use the same mathematical method to analyze the sound. They must invent a completely new way to do it without infringing on Acarix's rights. 3. The "first-mover" advantage They are the first to have had this written into the system as a recognized method. Doctors' habit: Once cardiologists have learned to use "acoustic rule-out" and have entered the code into their medical record systems, they are very reluctant to switch to something else. The database: Acarix has data from over 60,000 patients. Their AI is "trained" better than anyone else's because they have the largest library of heart sounds in the world. A competitor starts with 0 data. Conclusion: They have created a situation where they are the "gatekeeper" for acoustic cardiac diagnostics. If others want to enter this market, they must either: Spend 5-10 years developing their own (different) technology and clinical studies. Or (which is more likely in MedTech) buy Acarix to gain access to their patents and their "line in the system." This is precisely why a strategy of holding the stock long-term makes sense. The more they get "written into" official medical guidelines, the more valuable their patented "line" becomes.
- ·13.2.
- 13.2.13.2.Acarix (Q4 review): A solid end to 2025 Research Update Friday February 13 Redeye provides an update following Acarix’s Q4 2025 report. We view the report and recent activities positively, highlighting the continued growth in patch sales and CADScor system deliveries in the US, alongside progress in other key markets through its partner-led model. Following the report, we have made some revisions to our estimates, primarily regarding our projected US revenue ramp-up and the company’s ongoing geographical expansion.
- ·13.2.I believe it will go up when a good order comes in or if there is a new approval. Otherwise, it will probably go up and down for a while longer. I am, however, staying in the boat now.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
49 648
Myynti
Määrä
51 196
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 900 | - | - | ||
| 112 | - | - | ||
| 2 | - | - | ||
| 250 | - | - | ||
| 4 876 | - | - |
Ylin
0,309VWAP
Alin
0,29VaihtoMäärä
0,5 1 820 563
VWAP
Ylin
0,309Alin
0,29VaihtoMäärä
0,5 1 820 563
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧13 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 12.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenWhere do we think the price is moving towards this year 0,4sek·2 t sittenThey have just scaled up production for the second time. I expect an increase again by summer. The share price has not changed since the first time, which will soon lead to an upward jump when the effect of the sales is in Acarix's pocket. In addition, the company's expenses have constantly become proportionally smaller. Countless calculations can be made, but 1-2,5 kroner is within reach by year-end. This is just playing with numbers, and not a call to buy.
- ·13.2.Aamir to Redeye today: "Doubling our production capacity in a very near future"·2 päivää sittenWonderful news. It will be needed. Not a moment too soon.·1 päivä sittenHere's something about what I was talking about. What I am referring to is the incredibly important milestone where the CADScor system received its own unique CPT code (Category I CPT code) in the US healthcare system. In practice, this is what is called getting "its own line in the system," and it changes everything for the business model. Here are the most important points about what this means for Acarix: Direct payment (Reimbursement): Before the code was introduced, doctors and hospitals had to struggle with manual paperwork or use more generic codes to get the costs of a CADScor test covered. With its own line in the system, there is now an established procedure and a clear price for what insurance companies (including Medicare) must pay for a test. Massive growth in the USA: The code truly came into effect in January 2024. This is the primary reason why we saw the explosive growth in the US market during 2025, which we have just seen in the annual report. This makes it extremely much easier for sales teams (like those from CompleMed) to convince cardiologists to adopt the system, because they now know exactly how they will get their money back. Price per test: The average reimbursement in the USA is now around 300 USD per test. Since a patch only costs a fraction of this, it is a very good business for medical clinics to use CADScor as the primary screening tool. Validation: Obtaining a "Category I CPT code" is a long and difficult process at the AMA (American Medical Association). It serves as a seal of approval for the technology and proves that the method is clinically recognized and necessary. This is absolutely essential regarding Acarix's "moat" (protection against competitors). It's not just any "line in the system" – it's a line built around their completely unique, patented technology. Here's how they have "locked" the market so others can't just copy them: 1. The CPT code is "tailored" for acoustics When Acarix received their CPT code in the USA (originally 0714T, now often billed under more established codes), it was described specifically as an "acoustic analysis of heart sounds via AI." Why this is good for you: If a competitor comes with a new machine that, for example, measures electrical impulses (ECG) or heat, they cannot use Acarix's line in the system. They would have to start all over again applying for their own code – a process that takes many years and costs millions. 2. Patents: The technical wall Acarix holds over 45 patents across 12 patent families. These patents cover not just the machine itself, but the very way they filter out noise and find the very faint "murmurs" (turbulence) in the coronary arteries. No shortcuts: Other companies may not use the same mathematical method to analyze the sound. They must invent a completely new way to do it without infringing on Acarix's rights. 3. The "first-mover" advantage They are the first to have had this written into the system as a recognized method. Doctors' habit: Once cardiologists have learned to use "acoustic rule-out" and have entered the code into their medical record systems, they are very reluctant to switch to something else. The database: Acarix has data from over 60,000 patients. Their AI is "trained" better than anyone else's because they have the largest library of heart sounds in the world. A competitor starts with 0 data. Conclusion: They have created a situation where they are the "gatekeeper" for acoustic cardiac diagnostics. If others want to enter this market, they must either: Spend 5-10 years developing their own (different) technology and clinical studies. Or (which is more likely in MedTech) buy Acarix to gain access to their patents and their "line in the system." This is precisely why a strategy of holding the stock long-term makes sense. The more they get "written into" official medical guidelines, the more valuable their patented "line" becomes.
- ·13.2.
- 13.2.13.2.Acarix (Q4 review): A solid end to 2025 Research Update Friday February 13 Redeye provides an update following Acarix’s Q4 2025 report. We view the report and recent activities positively, highlighting the continued growth in patch sales and CADScor system deliveries in the US, alongside progress in other key markets through its partner-led model. Following the report, we have made some revisions to our estimates, primarily regarding our projected US revenue ramp-up and the company’s ongoing geographical expansion.
- ·13.2.I believe it will go up when a good order comes in or if there is a new approval. Otherwise, it will probably go up and down for a while longer. I am, however, staying in the boat now.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
49 648
Myynti
Määrä
51 196
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 900 | - | - | ||
| 112 | - | - | ||
| 2 | - | - | ||
| 250 | - | - | ||
| 4 876 | - | - |
Ylin
0,309VWAP
Alin
0,29VaihtoMäärä
0,5 1 820 563
VWAP
Ylin
0,309Alin
0,29VaihtoMäärä
0,5 1 820 563
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 820 563 | 1 820 563 | 0 | 0 |